Last reviewed · How we verify

Teva Branded Pharmaceutical Products R&D LLC — Portfolio Competitive Intelligence Brief

Teva Branded Pharmaceutical Products R&D LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TV-44749 TV-44749 phase 3 TRPV1 antagonist TRPV1 (Transient Receptor Potential Vanilloid 1) Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. Grünenthal GmbH · 1 shared drug class
  3. Kissei Pharmaceutical Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Teva Branded Pharmaceutical Products R&D LLC:

Cite this brief

Drug Landscape (2026). Teva Branded Pharmaceutical Products R&D LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/teva-branded-pharmaceutical-products-r-d-llc. Accessed 2026-05-17.

Related